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Drug deliveryL-Maurocalcine (L-MCa) is the ﬁrst reported animal cell-penetrating toxin. Characterizing its cell penetration
properties is crucial considering its potential as a vector for the intracellular delivery of drugs. Radiolabeling is
a sensitive and quantitative method to follow the cell accumulation of a molecule of interest. An L-MCa analog
containing an additional N-terminal tyrosine residue (Tyr-L-MCa) was synthesized, shown to fold and oxidize
properly, and successfully radioiodinated to 125I-Tyr-L-MCa. Using various microscopy techniques, the average
volume of the rat line F98 glioma cells was evaluated at 8.9 to 18.9 × 10−7 μl. 125I-Tyr-L-MCa accumulates within
cells with a dose-dependency similar to the one previously published using 5,6-carboxyﬂuorescein-L-MCa. Ac-
cording to subcellular fractionation of F98 cells, plasma membranes keep less than 3% of the peptide, regardless
of the extracellular concentration, while the nucleus accumulates over 75% and the cytosol around 20% of the ra-
dioactive material. Taking into account both nuclear and cytosolic fractions, cells accumulate intracellular con-
centrations of the peptide that are equal to the extracellular concentrations. Estimation of 125I-Tyr-L-MCa cell
entry kinetics indicate a ﬁrst rapid phase with a 5 min time constant for the plasma membrane followed by
slower processes for the cytoplasm and the nucleus. Once inside cells, the labeled material no longer escapes
from the intracellular environment since 90% of the radioactivity remains 24 h after washout. Dead cells were
found to have a lower uptake than live ones. The quantitative information gained herein will be useful for better
framing the use of L-MCa in biotechnological applications. This article is part of a Special Issue entitled: Calcium
Signaling in Health and Disease. Guest Editors: Geert Bultynck, Jacques Haiech, Claus W. Heizmann, Joachim
Krebs, and Marc Moreau.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Crossing cellular membranes represents amajor hurdle in current drug
development. Cell-penetrating peptides (CPP) are molecular vectors that
enter cells and allow the intracellular delivery of a number of bioactivemol-
ecules such as drugs, peptides, proteins, oligonucleotides/cDNA/RNA, and
nanoparticles [1–3]. Originally isolated from the venom of the scorpion
Scorpio maurus palmatus [4], L-maurocalcine (L-MCa) is a highly basic, pos-
itively charged, 33-mer peptide that efﬁciently binds to the ryanodine re-
ceptor in skeletal muscles and promotes channel opening and calcium
release from the sarcoplasmic reticulum. The binding site of L-MCa on theSignaling in Health and Disease.
Heizmann, Joachim Krebs, and
euroscience Institute, Site Santé
le Cedex 09, France. Tel.: +33
eWaard).ryanodine receptor has been identiﬁed as cytoplasmic [5], suggesting that
cytoplasmic application is required for its pharmacological effect. The fast
kinetics (few seconds) at which extracellular application of L-MCa
triggers internal Ca2+ release indicates that the peptide should be
able to easily translocate through the plasma membrane [6]. According
to 1H NMR analysis, the peptide presents three disulﬁde bridges (Cys3–
Cys17, Cys10–Cys21 and Cys16–Cys32) and folds along an inhibitor cyste-
ine knot pattern [4,7]. It contains three β-strands from amino acid resi-
dues 9–11 (strand 1), 20–23 (strand 2), and 30–33 (strand 3) with
strands 2 and 3 forming an antiparallel β-sheet (Fig. 1A). Several lines
of experimental evidence indicate that L-MCa is a member of the expo-
nentially growing family of CPPs [6,8–13]. The peptide is highly efﬁcient
in entering a variety of cell types compared to other popular CPP such as
TAT or penetratin. It presents a low toxicity proﬁle (absence of
toxicity at concentrations above 10 μM) [8], penetrates at lower
concentrations [14], and efﬁciently accumulates into the cytoplasm
which is a highly desirable feature for many biotechnological
applications that require the use of CPP. Therefore, a quantitative
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tance considering its potential as a vector for the improved delivery of
therapeutic compounds. Radiolabeling represents the most sensitive
and quantitative method to follow the quantitative entry of a cell pen-
etrating peptide of interest. Radioiodination is a widely used method
for radiolabeling of chemical compounds since the presence of iodine
would poorly affects the structural properties of the molecule of inter-
est. Speciﬁcally, 125I radiolabeling is commonly performed for in vitro
radioligand interaction and in vivo biodistribution studies [15,16].
For the purpose of radiolabeling of L-MCa, we synthesized an analog
with an extra amino-terminal tyrosine residue, termed Tyr-L-MCa,
that still possesses the pharmacological properties of wild-type L-
MCa. Next, we quantitatively investigated the cell penetration prop-
erties of the radioiodinated Tyr-L-MCa using the rat F98 glioma cellFig. 1. Properties of the Tyr-L-MCa analog. (A) Primary structure of L-MCa. The disulﬁde bridge conn
β-strands are indicated by arrows. Blue residues denote basic amino acids. (B) Stimulationof [3H]-r
explains why L-MCa stimulation of binding is limited. No signiﬁcant differences were observed
radiolabeling. Note the homogeneous labeling of the peptide by 125I. (D) Cell viability assay by ﬂ
level. (E) Cell viability assay by ﬂow cytometry for F98 cells after 2 h incubation with 33 μM Ty
0.1% saponin. Note the extensive cell death produced by saponin. (G) Proportion of live F98 cellsline and a precise evaluation of cell volume by Digital Holographic
Microscopy (DHM) or by confocal microscopy (CM). The results of the
present study will be useful for future in vivo biodistribution studies of
MCa.
2. Material and methods
2.1. Materials
N-α-Fmoc-L-amino acid, Wang-Tentagel resin and reagents used
for peptide synthesis were obtained from Iris Biotech. Solvents were
analytical grade products from Acros Organics. Acetonitrile was High
Performance Liquid Chromatography (HPLC) gradient grade from
Fischer Scientiﬁc and triﬂuoroacetic acid (purum ≥98%) from Flukaectivity is shownby lines connecting the six semi-cystine residues. The positions of the three
yanodine bindingonto SRvesicles. Experimentally, bindingwas performedat pCa=5which
between the efﬁcacies of L-MCa and Tyr-L-MCa. (C) RP-HPLC proﬁle of 125I-Tyr-L-MCa after
ow cytometry for control F98 cells. The ethidium-D1 ﬂuorescence level measures cell death
r-L-MCa. (F) Cell viability assay by ﬂow cytometry for F98 cells after 5 min incubation with
for control, saponin and Tyr-L-MCa conditions.
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Aldrich, hydrogen peroxide 30% in water (w/w) from Carlo Erba and
Na125I (3.7 GBq/ml) from Perkin Elmer. DMEM F-12 medium with or
without phenol red, fetal bovine serum, Trypsin-EDTA, rhodamine-
conjugated concanavalin A and live/dead viability/cytotoxicity kit
were obtained from Invitrogen. Protease inhibitors (cOmplete Min,
EDTA-free) were from Roche diagnostics.
2.2. Synthesis of Tyr-L-MCa by solid-phase
Tyr-L-MCa with an extra N-terminal tyrosyl residue was synthetized
to allow L-MCa radioiodination. Chemical synthesis of Tyr-L-MCa
was performed as previously described [17] with the following mod-
iﬁcations. Brieﬂy, Tyr-L-MCa was chemically synthesized by the
solid-phase peptide synthesis (SPPS) method [18] using an automated
peptide synthesizer (CEM© Liberty). The peptide chain was assembled
stepwise on 0.24 mEq of Fmoc-L-Arg(Pbf)-Wang-Tentagel resin using
0.24 mmol of N-α-ﬂuorenylmethyloxycarbonyl (Fmoc) L-amino-acid
derivatives. The side-chain protecting groups were Trityl for Cys
and Asn, tert-butyl for Ser and Tyr, Thr, Glu and Asp, Pbf for Arg,
and tert-butylcarbonyl for Lys. Reagents were at the following
concentrations: 0.2 M Fmoc-amino-acids (Fmoc-AA-OH in dimeth-
ylformamide (DMF)), 0.5 M activator (2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexaﬂuorophosphate in DMF), 2M acti-
vator base (diisopropylethylamine in N-methyl-pyrrolidone) and
deprotecting agent (5% piperazine/0.1 M 1-hydroxybenzotriazole
in DMF), as advised by PepDriver (CEM©). After peptide chain as-
sembly, the resin was treated with a mixture of triﬂuoroacetic acid/
water/triisopropylsilane/1,4-dithiothreitol (92.5/2.5/2.5/2.5) for 4
h at room temperature. The peptide mixture was then ﬁltered to
eliminate the resin and the ﬁltrate was precipitated by adding cold
t-butylmethyl ether. The crude peptide was pelleted by centrifuga-
tion (10,000 ×g, 15 min) and the supernatant was discarded. The
crude and reduced Tyr-L-MCa was submitted to oxidation for disul-
ﬁde bridge formation in 0.1 M Tris/HCl buffer at pH 8.2 during
3 days at room temperature. Oxidized/folded Tyr-L-MCawas then puri-
ﬁed by HPLC using a Vydac C18 column (218TP1010, 250 × 10 mm).
Elution of the peptide was performed with a 10–60% acetonitrile linear
gradient containing 0.1% triﬂuoroacetic acid (TFA) over 40 min. The
purity of the collected fraction was analyzed by reversed phase
(RP)-HPLC using analytical C18 column (Vydac, 218TP104, 10 μm,
250 × 4.6mm). Tyr-L-MCawas characterized byMALDI-TOFmass spec-
trometry. Samples were mixed 1:1 (v/v) with 10 mg/ml α-cyano-4-
hydroxycinnamic acid (HCCA) before spotted onto a MALDI target
plate. Mass spectrometry analyses were performed on a 4800 MALDI-
TOF/TOF instrument (ABSciex). MS spectra were acquired in positive
ion reﬂector mode over a mass range of 800–6000 m/z.
2.3. Radiolabeling of Tyr-L-MCa using lactoperoxidase
125I-Tyr-L-MCa was prepared using a direct iodination procedure
with lactoperoxidase/H2O2 system as oxidant. Brieﬂy, 37MBq of 125I
were added to 10 μg of Tyr-MCa in phosphate buffer (50 mM,
pH 7.4). The reaction was allowed to proceed for 30 min at room
temperature after addition of lactoperoxidase and H2O2 at a ﬁnal
concentration of 0.5 μM and 25 μM respectively. Radioiodinated
Tyr-L-MCa was analyzed by HPLC immediately and radiochemical
purity higher than 95% was achieved, thereby obviating the need
for a puriﬁcation step. A single peak of radioiodinated 125I-Tyr-L-
MCa was observed. The compound was stable for over 48 h. A simi-
lar labeling was performed with Na127I according to the same pro-
cedure. In these conditions, the compound was shown to be
monoiodinated (not shown). The resulting compounds, 125I-Tyr-L-
MCa and 127I-Tyr-L-MCa, were mixed in order to obtain a speciﬁc ac-
tivity of 0.4 MBq/nmol of Tyr-L-MCa (activimeter Capintec).Hereafter, we shall speak about 125I-Tyr-L-MCa although it reﬂects
a mixture of 125I-Tyr-L-MCa and 127I-Tyr-L-MCa.
2.4. F98 glioma cell culture
All experiments were performed using the F98 glioblastoma cancer
cell line (undifferentiated malignant glioma rat cell line from ATCC)
maintained at 37 °C in 5% CO2 in DMEM F-12 medium supplemented
with 2% (v/v) heat-inactivated fetal bovine serum and 10,000 units/ml
streptomycin and penicillin. Cells were platted on 24 well plates
(Falcon; 700,000 cells/well) and grown 24 h until they reach 90%
conﬂuence.
2.5. Cell counting
To get a precise estimate of the cell number present in each well
at the time where cell penetration experiments are performed with
125I-Tyr-L-MCa, F98 cells were counted by ﬂow cytometry analyses
with live cells using a Becton Dickinson Accuri C6 ﬂow cytometer
(BD Biosciences). Data were obtained and analyzed using BD Accuri
C6 software. Live cells were gated by forward/side scattering.
2.6. Evaluation of F98 cell death
Cells were incubated with or without various concentrations of
Tyr-L-MCa during 2 h. Cells were washed with PBS and washes
were conserved. They were then treated with 0.05% trypsin-EDTA
for 5 min at 37 °C to detach them from the support. Cells were col-
lected and resuspended in DMEM-F12 with 2% fetal bovine serum
along with the initial washes. For one series of control cells, 0.1% sa-
ponin was added just before centrifugation to induce cell death. All
cell conditions (control, Tyr-L-MCa and saponin) were centrifuged
at 800 ×g during 5min. The pelletswere resuspended in 200 μl of stain-
ing mix according to Invitrogen recommendations. Cells were left in
the dark for 15 min at room temperature before analyses by ﬂow cy-
tometry using the LIVE/DEAD® Viability/Cytotoxicity Kit of
Invitrogen. This kit quickly discriminates live from dead cells by si-
multaneously staining with green-ﬂuorescent calcein-AM to indicate
intracellular esterase activity and red-ﬂuorescent ethidium
homodimer-1 to indicate loss of plasmamembrane integrity. Similar re-
sults were obtained with 125I-Tyr-L-MCa.
2.7. Estimation of F98 cell volume by Digital Holographic Microscopy or
confocal microscopy
Digital Holographic Microscopy (DHM) is an interferometric tech-
nique that makes possible the imaging and measurement of the phase
retardation through transparent biological specimen [19]. Because it is
based on the interference of coherent light (lambda 658 nm) a high
precision (nm order) can be obtained in optical thickness measure-
ments. Under the hypothesis of invariance of the refractive indexwithin
the cytosol, it may be admitted that the measured optical thickness is a
good estimate of the quantity of matter traversed by light [20]. There-
fore, the average F98 cell volume was estimated by integrating the
optical thickness over the projected area of each cell.
To evaluate the F98 cell volume by confocal microscopy, cell plasma
membranes were stained with 50 μg/ml concanavalin A-rhodamine for
5 min. Next, cells were washed with phosphate buffered saline (PBS)
and incubated inDMEMwithout phenol red. Live cells were then imme-
diately analyzed by confocal laser scanning microscopy using a Zeiss
LSM operating system. Rhodamine was sequentially excited (at
561 nm) and emission ﬂuorescence (at 590 nm) was collected. Stacks
of 17 to 22 confocal images were taken by steps of 1 μm on the z-axis
to cover the entire depth of the cells. Globally, F98 cells were quite
thick but some images of the stacks may not contain any information.
Next, a dedicated Image J macro was developed to reconstruct the 3-D
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membrane boundaries.2.8. Quantitative evaluation of the cell penetration of 125I-Tyr-L-MCa
F98 cells were incubated with various concentrations of radio-
iodinated 125I-Tyr-L-MCa (33 nM to 10 μM) in DMEM F-12 culture
medium (200 to 400 μl per well) without serum or antibiotics at 37 °C
for 2 h to allow cell penetration. For the estimation of the kinetics of
cell entry of the compound, the time of incubation could be shortened
as indicated. Each concentration contained 2.5% of 125I-radiolabeled
peptide and 97.5% of 127I-labeled peptide to diminish the quantity of ra-
dioactive peptide to handle. After incubation, the cells were washed
twice with PBS to remove excess extracellular peptide. They were
then treated with 0.05% trypsin-EDTA for 5 min at 37 °C to (i) degrade
any remaining extracellular 125I-Tyr-L-MCa and (ii) detach F98 cells
from the surface. Cells were collected and resuspended in DMEM-F12
with 2% fetal bovine serum. Cells were centrifuged at 800 ×g during
5 min. The pellet was resuspended in PBS and cells were then centri-
fuged a second time in the same conditions. Of note, for each one of
the centrifugation and washing steps, resuspended cells were trans-
ferred to new tubes to eliminate any extracellular radioiodinated 125I-
Tyr-L-MCa or trypsin-induced fragment that may be potentially present
by sticking to the plastic. Cells were resuspended in 1 ml of lysis buffer
(in mM: Tris 20, NaCl 150, DTT 1, sucrose 250, pH 8.0 along with prote-
ase inhibitors) and incubated on ice for 5min. Next, cells weremechan-
ically disrupted using a potter. Subcellular fractionation was performed
as follows. First, the cell lysateswere centrifuged at 900×g for 20min and
the pellet containing the cell nuclei (F98-N) was collected. Next, the
supernatant was collected and centrifuged at 50.000 ×g for 60 min. The
pellet containing the plasma membrane was kept (F98-PM) along with
the supernatant that represents the cytoplasm (F98-C). Both pellets
were resuspended in 500 μl distilled water for counting. This subcellular
fractionation method separates membrane-bound (F98-PM) from intra-
cellular 125I-Tyr-L-MCa (F98-N + F98-C) providing an estimate of cell
penetration of the peptide into the cytoplasm. Counting of radioactivity
was carried out by gamma-well counter.2.9. Determination of the intracellular concentration of 125I-Tyr-L-MCa
Knowing the precise cell number per well, the average cell volume
and the speciﬁc activity of 125I-Tyr-L-MCa,wewere able to convert counts
per min to intracellular peptide concentration. The concentration of
radioiodinated Tyr-L-MCa is provided in μMandwas calculated according
to the equation f0= (((cpm/cell number)/a)/b)/cell volume. The value a
is a constant value of the gamma-well counter (a= 35515679 to convert
cpm values in MBq). The value b is the speciﬁc activity of Tyr-L-MCa that
has been used for the preparation of dilutions. Only the added values of
F98-N and F98-C radioactivity were taken into account to quantify cell
penetration. F98-PM values were discarded.2.10. Kinetic of cellular leakage of 125I-Tyr-L-MCa
F98 cells were incubated with 1 μMof 125I-Tyr-L-MCa in DMEM F-12
culture medium without serum or antibiotics at 37 °C for 2 h. The cells
were then washed three times with PBS to remove excess extracellular
peptide, and then completed with DMEM F-12 medium. At different
times (0, 1, 2, 3, 4, 5, 6 and 24 h), a sample of 100 μl of medium was
taken for radioactivity counting and replaced by 100 μl of fresh complete
medium. The value obtained was corrected by a factor of 4 (100 μl taken
out of 400 μl of medium). A control was performedwithout cells to dem-
onstrate that the plastic of thewells did not release any radioactivity. The
quantity of radioactivity released by the cells was evaluated as a ratio of
total cell radioactivity as determined previously.2.11. [3H]-ryanodine binding on ryanodine receptors from skeletal muscle
heavy SR vesicles
Heavy sarcoplasmic reticulum (SR) vesicles were prepared as de-
scribed [11]. Protein concentration was measured by the Biuret method.
Heavy SR vesicles (1 mg/ml) were incubated at 37 °C for 2 h in an
assay buffer composed of 10 nM [3H]-ryanodine, 150 mM KCl, 2 mM
EGTA, 2 mM CaCl2 (pCa = 5), and 20 mMMOPS, pH 7.4. 200 nM L-MCa
or Tyr-L-MCa was added prior to the addition of heavy SR vesicles.
[3H]-ryanodine bound to heavy SR vesicles was measured by ﬁltration
through Whatman GF/B glass ﬁlters followed by three washes with
5 ml of ice-cold washing buffer composed of 150 mM NaCl, 20 mM
HEPES, pH 7.4. [3H]-ryanodine retained on the ﬁlters was measured
by liquid scintillation. Nonspeciﬁc binding was measured in the
presence of 80 μM unlabeled ryanodine. The data are presented as
mean ± S.E. Each experiment was performed in triplicate.
3. Results
3.1. Tyr-L-MCa: a functional MCa analog for iodination
L-MCa itself lacks a tyrosine residue for radio-iodination of the
peptide. To this end, we produced a new analog of L-MCa with an
extra amino-terminal tyrosine residue. Earlier observations had
demonstrated that N-terminal-modiﬁed analogs of L-MCa could be
easily produced since the addition of an extra-biotinylated lysine
residue iswithout impact on the proper folding/oxidation of the peptide
[9]. MS analyses (MALDI-TOF technique) of crude and folded/oxidized
Tyr-L-MCa provide experimental molecular masses (M + H)+ of
4026.9 and 4020.8 Da, respectively. The shift in experimentalmolecular
mass of 6.1 Da upon folding/oxidation is in agreement with the en-
gagement of all six cysteine residues in the formation of three disul-
ﬁde bridges. Since the activity of L-MCa is strictly dependent on the
proper/folding of the peptide [21] and that this activity is not altered
by N-terminal modiﬁcation [6,9], it is expected that Tyr-L-MCa should
have preserved its pharmacological effect. Fig. 1B illustrates that this is
indeed the case. As shown, Tyr-L-MCa turned as potent as L-MCa itself
in stimulating the binding of [3H]-ryanodine onto skeletal muscle
ryanodine receptors from SR vesicles. Next, since Tyr-L-MCa remained
functional, the peptide was enzymatically iodinated using the
lactoperoxidase/H2O2 system. Under the experimental conditions
described radiochemical purity higher than 95% was achieved. This
was further illustrated in the HPLC proﬁle of the compound (Fig. 1C).
125I-Tyr-L-MCa remained stable for over 24 h. 127I iodination was also
used to prepare 127I-Tyr-L-MCa instead of 125I-Tyr-L-MCa to lower the
speciﬁc activity and the quantity of radioactivity to handle. Modeling
experiments illustrates the relative position of the extra iodinated
tyrosine residue onto L-MCa (Fig. 2).
3.2. Tyr-L-MCa lacks cell toxicity and is partially degraded by trypsin
treatment
We ﬁrst assessed that Tyr-L-MCa does not induce cell death that may
alter the evaluation of cell penetration. For that purpose, we used rat
glioma F98 cells because we plan to use L-MCa as a vector for the delivery
of chemo-active drugs in later studies. As shown by ﬂow cytometry, incu-
bating F98 cells 2 hwith 33 μMTyr-L-MCadoes not induce any speciﬁc cell
death compared to the control condition (Fig. 1D, E). The control
condition contained about 3.3% of dead cells compared to the 2.6% of
the Tyr-L-MCa condition. In contrast, 5 min incubation with 0.1% saponin
has a drastic effect on cell survival since the proportion of dead cells
reached 93.4% (Fig. 1F). Similar results were obtained for a set of
Tyr-L-MCa concentration that all indicate that this vector is non-toxic
for F98 cells (Fig. 1G). Similar observationsweremadewith F98 cells in-
cubated with 125I-Tyr-L-MCa indicating that gamma radiation did not
Fig. 2.Modeled 3D structure of 125I-Tyr-L-MCa. The structure was modeled starting with L-MCa as a structural basis (1C6W from the Protein Database). The extra tyrosine residue is in
yellow and the iodine on the tryrosine ring in red. The positively charged amino acid residues of L-MCa are also highlighted.
2360 C. Tisseyre et al. / Biochimica et Biophysica Acta 1843 (2014) 2356–2364add a layer of cell toxicity in the frame of our experiments (data not
shown).
3.3. Cell penetration properties of 125I-Tyr-L-MCa
Production of the 125I-Tyr-L-MCa compound with high radiochemical
purity is an opportunity to quantify the cell penetration of L-MCa into
cells. Earlier labeling of L-MCa with a ﬂuorescence indicator provided
only semi-quantitative information [11]. We ﬁrst designed a subcellular
fractionation protocol that was aimed at minimizing the contribution of
any externalmembrane-attached 125I-Tyr-L-MCa radioactivity associated
to F98 cells. This protocol includes trypsin treatment, many cell washes,
and a systematic transfer of the biologicalmaterial to newplastic tubes in
order to avoid possible attachment of any external 125I-Tyr-L-MCa to
plastic surfaces. Trypsin treatment was kept to the minimum because
its ﬁrst aim is to detach cells from the surface. Longer exposure would
result in better external 125I-Tyr-L-MCa degradation but also in cell dam-
agingwhich is not desirable. Fig. 3 illustrates that indeed a 5min trypsin
digestion after F98 cell incubation with 125I-Tyr-L-MCa results in only
limited peptide degradation. The appearance on the HPLC elution proﬁle
of a new leftward-shifted peak, which is superimposed to the remnantFig. 3. RP-HPLC proﬁle of 125I-Tyr-L-MCa following 5 min of incubation with trypsin. The
major peak is the intact 125I-Tyr-L-MCa, while the peaks denoted by the arrows reﬂect de-
graded products.peak of the original 125I-Tyr-L-MCa compound, indicates that the
trypsin-mediated degradation is only partial. To further minimize the
potential quantitative contribution of any cell membrane-bound 125I-
Tyr-L-MCa, the plasma membrane was quantiﬁed as a separate entity
and the radioactivity associated to this subcellular fraction was exclud-
ed from our calculations of L-MCa cell entry and accumulation. Howev-
er, as we shall see later, the radioactivity associated with the plasma
membranewas extremely low indicating little accumulation of the pep-
tide in membrane fractions which further strengthens the reliance on
the protocol used to quantify cell entry.
The entire study was performed on the rat glioblastoma cancer cell
line F98maintained in culture. To assess the cell concentration achieved
by the 125I-Tyr-L-MCa, we ﬁrst determined two important parameters:
i) the cell number in each well and ii) the average volume of F98 cells.
The cell number in each culture well was established by FACS counting.
The average cell number was 403,754 ± 23,434 per well (n= 4wells).
This includes 96.7% of live cells and 3.3% of dead cells as deﬁned in
Fig. 1D. Next, we evaluated the average cell volume using two different
techniques: DHM and cell volume reconstruction through the acquisi-
tion of stacks of confocal images. Fig. 4A illustrates the optical thickness
image produced by DHM with gray levels coding for the optical thick-
ness. The surface reconstruction of the optical thicknesses is shown in
Fig. 4B. The volume of F98 cells can be obtained by integration of the op-
tical thickness inside the cell areas. A histogram illustrating individual
cell volume was constructed (Fig. 4C). Fitting the data provides an aver-
age cell volume of 8.9 × 10−7 ± 0.2 × 10−7 μl (n = 130 cells). We also
used z-stacks of CM images to reconstruct cell volumes, again by focusing
on individual cells. The boundaries of cells were provided by
concanavalin-A rhodamine staining of the plasma membranes. Using
this CM method instead of DHM, we come up with an average F98 cell
volume of 18.9 × 10−7 μl (n = 95 cells). There is thus a 2.12-fold differ-
ence in volume estimation using these two methods. DHM is likely a
more precise technique for volume estimation and we will rely on
the average DHM value to calculate the intracellular concentration
of 125I-Tyr-L-MCa. However, when applicable, the concentration values
will also be provided using the CM cell volume evaluation method in
parentheses.
First, we investigated how dead cells may affect the uptake of
125I-Tyr-L-MCa. The peptide being extremely basic it is possible that
dead cells, by exposing their DNA or their protein content, may overly
contribute to the measured signal. We therefore purposely compared
Fig. 4. Estimation of the average volume of F98 glioblastoma cells by DHM. (A) Optical thickness image produced by DHM, the gray levels are coding for the optical thickness. (B) Surface
reconstruction of the optical thicknesses. (C) Histogram showing the distribution of individual cell volumes, obtained by integrating the optical thickness inside the cell areas. Only individual
cells were used to evaluate cell volumes since touching cells could lead to overestimation. Cell fragments were also avoided for this analysis.
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33 μM 125I-Tyr-L-MCa with the amount found in dead cells, the cell
death being promoted by 0.1% saponin. As shown in Fig. 5A, dead cells
accumulate a surprisingly high level of radioactivity in each of the sub-
cellular fractions. In each case however, the level of activity was lower
than in live cells, indicating that cell death should not affect the mea-
surements on live cells signiﬁcantly. Fig. 5A also illustrates that the plas-
ma membrane is the subcellular fraction that accumulates the least
radioactivity compared to the cytoplasm and the nucleus. At this exter-
nal concentration, the plasma membrane represents 9.4% of the accu-
mulated radioactivity. In contrast, the cytoplasm and the nucleus of live
cells accumulate each 25.6% and 64.7%, respectively. These proportions
were however altered in dead cells with respective accumulations of
15.7% (plasma membrane), 45.1% (cytoplasm) and 32.2% (nucleus). The
comparatively good accumulation of 125I-Tyr-L-MCa in the
cytoplasmic fraction of dead cells is probably linked to the effect of
saponin on the plasma membrane. Since saponin should not affect the
membrane of the nucleus, we still observe a quantitative difference in
the accumulation of 125I-Tyr-L-MCa radioactivity in dead cells compared
to live ones. The result also indicates that the intracellular concentration
of 125I-Tyr-L-MCa should not exceed by far the extracellular concentra-
tion of the compound since passive accumulation within permeabilized
cells resembles the accumulation within live cells.
We examined the concentration-dependent uptake of 125I-Tyr-L-MCa
by live F98 cells using extracellular concentrations ranging from 3.3 nM
to 10 μM for a 2 hour-incubation time. We then assessed the cumulated
radioactivitywithin each subcellular fraction. As shown in Fig. 5B, evident
accumulation of 125I-Tyr-L-MCa occurs essentially within the cytoplasm
and the nucleus at a concentration as low as 300 nM. Increasing
extracellular concentrations of the 125I-Tyr-L-MCa also produceincreasing elevations of the radioactivity within each fraction with
similar dose-dependent proﬁles. In the result shown here, there was
almost no accumulation within the plasma membrane fraction. There
is no sign of saturation in full agreement with earlier observations
using L-MCa tagged with ﬂuorescent dyes [10,11]. The cell count, the
average DHM-assessed F98 cell volume and the speciﬁc activity of
125I-Tyr-L-MCa have been used to convert the experimental cpm data
into average cell concentrations of 125I-Tyr-L-MCa. Only cumulated cpm
values from the cytoplasm and the nucleus were taken into account
since the radioactivity associated to the plasma membrane fraction
could bear some 125I-Tyr-L-MCa from the outer leaﬂet of the membrane
that would not be digested by the trypsin treatment as shown earlier.
Obviously, this may lead to underestimation of the total accumulated
125I-Tyr-L-MCa in F98 cells but this was preferable to a slightly
overestimated concentration, the plasma membrane accounting for
only a small fraction of the total radioactivity (b10% at all concentra-
tions tested and for each experiment we performed). According to
the method, we show a close correspondence in the intracellular
concentration of 125I-Tyr-L-MCa compared to the extracellular con-
centration (Fig. 5C). For instance at 1 μM external 125I-Tyr-L-MCa,
F98 cells accumulated 2.41 μM of the peptide according to DHM vol-
ume estimation (1.14 μM according to CM-based volume estima-
tion). Examining the internal concentration of 125I-Tyr-L-MCa as a
function of the external concentration indicates that the concentra-
tion ratio (internal/external) is higher at lower external concentra-
tions than at high external concentrations. This was marked at 10 nM
where penetration is barely detected with this cell penetrating peptide.
Fitting the experimental datawith a decreasing exponential curve yields
a concentration ratio of 2.45 according to DHM data (or 1.15 according
to CM data) (Fig. 5C, inset).
Fig. 5. Estimation of the accumulation properties of 125I-Tyr-L-MCa in F98 cells. (A) Total
radioactivity accumulated in subcellular fractions of live and dead cells (plasma membrane,
cytoplasm, andnucleus). Radioactivitywas alsomeasured for control live cells in the absence
of 125I-Tyr-L-MCa. No signiﬁcant counts could be measured. Extracellular concentration of
125I-Tyr-L-MCa used: 33 μM. 2 h incubation. (B) Concentration dependent accumulation of
125I-Tyr-L-MCa in subcellular fractions of live cells. 2 h of incubation with the radiochemical
compound. (C) Evaluation of the internal concentration of 125I-Tyr-L-MCa reached after 2 h
incubation of live F98 cells as a function of the external concentration of 125I-Tyr-L-MCa.
Inset: ratio of concentration as a function of the external 125I-Tyr-L-MCa. The datawere ﬁtted
with the following equation y= y0+ a.e−bx where y0= 2.45± 0.31, a= 27.1± 8.6 and
b = 0.098 ± 0.031.
Fig. 6.Kinetics of 125I-Tyr-L-MCa accumulationwithin thedifferent subcellular compartments
of F98 cells. (A) Kinetics of 125I-Tyr-L-MCa accumulation within the plasma membrane
fraction of F98 cells. The data were ﬁtted with the equation y = a × (1 − e−bx)
where a = 99.8 ± 19.7 and b = 0.20 ± 0.12 min−1. (B) Kinetics of 125I-Tyr-L-MCa ac-
cumulation within the cytoplasmic fraction of F98 cells. Parameters after ﬁtting were:
a = 94.2 ± 8.1 and b = 0.10 ± 0.02 min−1. (C) Kinetics of 125I-Tyr-L-MCa accumulation
within the nuclear fraction of F98 cells. Parameters after ﬁtting were: a = 127.6 ± 23.5
and b= 0.025± 0.007min−1. For all these experiments we used 1 μMof 125I-Tyr-L-MCa.
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For a 125I-Tyr-L-MCa accumulation in the nucleus, the peptide needs
ﬁrst to cross the plasma membrane, then to accumulate within the
cytoplasm, and should afterwards travel to the nucleus of F98 cells.
This sequence of events requires that the kinetics of accumulationwithin
each subcellular fraction should follow a logic time gradient. This point
was investigated by incubating F98 cellswith 1 μM125I-Tyr-L-MCa for var-
ious durations, fractionating the cells and counting the radioactivity asso-
ciated to each fraction (Fig. 6). As shown, the time constant for
radioactivity accumulation in the plasma membrane is τ = 5 min
(Fig. 6A). This value rises to τ = 10 min for the cytoplasm (Fig. 6B),
which remains quite rapid, and to τ= 20 min for the accumulation in
the nuclear fraction of F98 cells (Fig. 6C).125I-Tyr-L-MCa is heavily charged (net positive charge = +8) indi-
cating that it may be attracted to the internal face of the plasma mem-
brane because of the existence of the negative membrane potential. It
can be envisioned that while the cell entry of the peptide is facilitated
because of thismembrane potential, the same negative charges residing
in the cell may prevent the cell escape of the peptide. We investigated
this issue by examining the gradual release of radioactivity within the
externalmedium. As shown, F98 cells are extremely reluctant to release
the radioactivity once accumulation has occurred (Fig. 7). It is only after
24 h of washout time that about 8.9% of the radioactivity is released by
the cells.
Fig. 7. Kinetics of cell exit rate of 125I-Tyr-L-MCa from F98 cells. Time-dependent exit of
125I-Tyr-L-MCa from F98 cells expressed as a percentage of total intracellular labeled
peptide.
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L-MCa is the ﬁrst example of a folded and oxidized animal peptide
toxin acting as a CPP [6,8–12,14,21–24]. Since CPPs hold great promises
in the ﬁeld of drug delivery, it was therefore of great importance to de-
termine the precise cell entry characteristics of L-MCa. Radiolabeling
represents the most sensitive and quantitative method to quantify the
cell entry of a molecule of interest. To this aim we produced Tyr-L-MCa
that, as expected from earlier evidence, preserved proper folding and
oxidation, as well as the original pharmacological properties of L-MCa
and the resistance to proteolytic cleavage. The position of the extra
tyrosine residue ensured that iodination occurred in a convenient
way, without accessibility problems and without introducing structural
disturbances within the native sequence. Compared to other reporting
methods, the addition of an iodinated Tyr residue at the N-terminus of
L-MCa keeps structural alterations of the peptide to a minimum.
For the ﬁrst time, compared to all our earlier investigations using
ﬂuorochromes as reporters [10,11,14,21], we were able to extract
valuable quantitative information on the cell penetration properties
of 125I-Tyr-L-MCa. For that purpose, we used the rat glioblastoma F98
cell line and several critical parameters to assess the penetration prop-
erties. First, we precisely deﬁned the speciﬁc activity of 125I-Tyr-L-MCa
that allowed us to establish a precise correlation between measured
cpm values and peptide quantities. Then, we used DHM to evaluate
the cell volume and transform peptide quantities into intracellular con-
centrations. Finally, an adequate biochemical protocol combined to cell
sub-fractionation helped deﬁned cell compartments and informed on
the relative cell distribution of 125I-Tyr-L-MCa. It was striking to observe
that very little radioactivity is associated to the plasma membrane frac-
tion. This is coherent with earlier observations using MCa analogs
coupled to ﬂuorescent dyes. These vector/cargo couples were in most
cases not observed at the plasma membrane level on images gathered
by confocal microscopy, except on some occasions [10]. It was however
possible that the lipophilic environment of themembrane could quench
the ﬂuorescence of these dyes. Our data using iodinated Tyr-L-MCa
demonstrates that the plasmamembrane is not a compartment of pep-
tide accumulation on or in the cells. This indicates that the residency
timeof 125I-Tyr-L-MCawithin the plasmamembrane is very low, aﬁnding
that is consistent with the fast kinetics of cell accumulation within the
membrane. While the plasma membrane is an obligatory route of cell
entry for 125I-Tyr-L-M, the peptidemust useunstablemodes of interaction
with the plasma membrane components. The transient nature of these
interactions argues for a rapid crossing followed by a dilution process
within the cytoplasm. The kinetics of accumulationwithin the cytoplasm
is itself quite rapid (time constant of 10 min) but the degree of accumu-
lation is signiﬁcantly greater than in the plasma membrane. An interest-
ing observation is the accumulation of the peptide within the nucleus, to
a great proportion, indicating that the peptide that is transferred from thecytoplasm to the nucleus had to be freely moving in the cytoplasm and
could not be trapped within endosomes. This wouldn't have occurred if
the majority of the peptide had been captured in F98 cells by a form of
endocytosis such asmacropinocytosis.Wewere not able to assess the rel-
ative volumes occupied by the cytoplasm and the nucleus. These values
would however be meaningless to some extent as both compartments
are themselves sub-compartmentalized. However, the values of cpm
accumulation within these two compartments were closely related sug-
gesting that most likely passive equilibrium was reached in the concen-
trations of the labeled peptide. In any case, the ﬁnding that the peptide
is present in thenucleus contradicts other observations using dyes or pro-
teins as cargoes, as in all cases MCa analogs were mostly conﬁned to the
cytoplasmic region presumably because of cargo-oriented trapping into
endosomes [8–12,14]. In other cases, however, we found evidence for
nuclear accumulation of doxorubicin as cargo [22,25–27], indicating
that the matter of nuclear accumulation is cargo dependent. The reason
for the accumulation of 125I-Tyr-L-MCa in the nucleus has not been inves-
tigated. However, itmay be argued that the peptide freely crosses nuclear
pores and passively invades the nucleus. Because of its basic nature, it
may then be stabilized there by ionic interactions with DNA. This matter
may be studied later by using some of the small cell penetrating peptide
variants derived from L-MCa that lack the basic nature of the full-length
peptide [10,14].
The kinetics of accumulation within the plasma membrane and the
cytoplasm deserve another comment. The time constant of a few
minutes for the cell penetration of 125I-Tyr-L-MCa is in apparent contrast
with the second time scale required for L-MCa to trigger Ca2+ release
after external application [6]. This difference is unlikely to be due to
the extra-tyrosine residue or its labeling with iodine. The ryanodine
receptor activation requires less than 10 nM internal concentration.
However because of the peculiar location of the binding site of L-MCa
on the ryanodine receptor [5], at the interface of the cytoplasm and the
plasma membrane, it is possible that local L-MCa elevations may sufﬁce
to activate the ryanodine receptor. This would further be exaggerated
by the presence of up to four binding sites of L-MCa on the ryanodine re-
ceptor, with a single occupancy being sufﬁcient for activation. In addi-
tion, signiﬁcant Ca2+ signals are expected with the activation of very
few ryanodine receptors. Finally, considering the lipophilic environment
of the L-MCa binding site, the reversibility of interaction between L-MCa
and the ryanodine receptor is not evident. For all these reasons, we
therefore believe that the kinetics of cell entry and Cam release activation
cannot be easily compared.
Regarding peptide concentrations reached within the cell, we found
values indicating near passive distribution between the outside and
the inside of the cell. Precise estimation of cell concentration of
125I-Tyr-L-MCa is also linked to the precise estimation of cell volume.
We purposely used two techniques of cell volume investigation and
found closely related values. The close to 2-fold difference suggests
that our concentration values can be corrected by a factor of 2 as well.
In the worst-case scenario, the global concentration of the peptide in-
side cells would match the outside concentration of 125I-Tyr-L-MCa.
The estimated cell volume is of course the total cell volume and does
not take into account the volume loss that should be introduced by
the volume of many organelles such as mitochondria, endoplasmic
reticulum and the Golgi apparatus for instance, if the peptide does not
accumulate into these organelles. If we take this assumption as correct,
then we may assume that part of the peptide accumulation may occur
against the concentration gradient. Voltage-driven accumulation may
well represent one mechanism explaining how cells may cumulate
higher peptide concentrations than the outside. Cells are negatively po-
larized. The net positively charged L-MCa should be attracted by the
negative charges located underneath the plasma membrane. A second
potential mechanism may be local increases of the peptide concentra-
tion at the external side of the plasma membrane. L-MCa interacts
with negatively charged glycosaminoglycans [24] or negatively charged
lipids [8] and the positive charges of L-MCa may contribute to greater
2364 C. Tisseyre et al. / Biochimica et Biophysica Acta 1843 (2014) 2356–2364interactions, thereby locally increasing the peptide concentration. In
any case, the ﬁnding that the labeled peptide can barely escape the in-
tracellular environment is also evidence for the existence of an accumu-
lation process that is not only linked to passive redistribution of the
peptide into the cells. It indicates the existence of a strong asymmetry
in the ﬂuxes of Tyr-L-MCa through the membrane. This may be linked
to the asymmetric lipid composition or the existence again of a voltage
gradient across the plasma membrane.Acknowledgements
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